News

March 20, 2019

CHMP Favors EU Approval of Lynparza for Some Advanced Breast Cancers

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended the approval of Lynparza (olaparib) tablets for the treatment of advanced breast ... Read more

March 18, 2019

Vitamin C Might Reverse Stress-induced Driver of Breast Cancer, Study Says

News

Chronic stress and the consequent release of the stress hormone epinephrine may help breast cancer cells grow by helping them get more energy, a study in mice shows. This effect might ... Read more

March 15, 2019

FDA Grants Accelerated Approval to Tecentriq-Abraxane Combo for Some TNBC

News

The U.S. Food and Drug Administration has granted accelerated approval to a combination of Tecentriq (atezolizumab) and the chemotherapy Abraxane (nab-paclitaxel) for patients with advanced triple-negative breast cancer, making this the ... Read more

March 13, 2019

Thousands of Lives Spared Thanks to Screening, Treatment, Study Reports

News

Since 1989, between 384,000 and 615,000 women’s lives have been spared thanks to significant advancements in breast cancer screening methods and treatment, a study reports. The findings of the study, ... Read more

March 11, 2019

NeuVax/Herceptin Combo Promotes Disease-free Survival in TNBC

News

Long-term treatment with a combination of NeuVax (nelipepimut-S) and Herceptin (trastuzumab) is safe and extends the time without disease resurgence in women with triple-negative breast cancer, according to final results of a Phase 2b ... Read more

March 8, 2019

FDA Approves Under-the-skin Formulation of Herceptin for Certain Breast Cancers

News

The U.S. Food and Drug Administration (FDA) has approved an under-the-skin formulation of Genentech‘s breast cancer treatment Herceptin (trastuzumab), called Herceptin Hylecta. Also by Genentech, the treatment consists of a combination of trastumuzab and ... Read more

March 6, 2019

Imaging Agent May Provide Early Info About Benefits of Hormone Therapies for Breast Cancer

News

A new imaging agent that successfully measures changes in progesterone receptor (PR) levels may be used to determine if a breast cancer patient will respond to hormone therapies targeting the ... Read more

March 4, 2019

Cellular Barcoding Sheds Light on Spread, Drug Resistance of TNBC

News

Very few cancer cells within a triple negative breast tumor (TNBC) are able to spread and grow in distant organs (metastasize), although most are able to shed from the original ... Read more

March 1, 2019

Pfizer’s Biosimilar Zirabev Approved in E.U. for Advanced Breast, Other Cancers

News

Metastatic breast cancer patients in the European Union will have the possibility of being treated with a biosimilar of Avastin (bevacizumab), following the approval of Pfizer’s Zirabev (bevacizumab) as a more affordable ... Read more

February 27, 2019

Sacituzumab Govitecan Shinks Tumors in One of Three Metastatic TNBC Patients, Trial Shows

News

One in three women with metastatic triple-negative breast cancer — all of whom had received at least two prior treatments — saw their tumors shrink after receiving Immunomedics‘ investigational treatment sacituzumab govitecan as part ... Read more